We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Single Mutation Linked to Fatty Disorders of Liver and Skin

By LabMedica International staff writers
Posted on 05 Aug 2019
Print article
Image: A micrograph of non-alcoholic fatty liver disease (NAFLD). The liver has a prominent (centrilobular) macrovesicular steatosis (white/clear round/oval spaces) and mild fibrosis (green). The hepatocytes stain red. Macrovesicular steatosis is lipid accumulation that is so large it distorts the cell\'s nucleus (Photo courtesy of Wikimedia Commons).
Image: A micrograph of non-alcoholic fatty liver disease (NAFLD). The liver has a prominent (centrilobular) macrovesicular steatosis (white/clear round/oval spaces) and mild fibrosis (green). The hepatocytes stain red. Macrovesicular steatosis is lipid accumulation that is so large it distorts the cell\'s nucleus (Photo courtesy of Wikimedia Commons).
The common liver disorder non-alcoholic fatty liver disease (NAFLD) has been found to share a genetic linkage with Chanarin-Dorfman syndrome, a rare skin condition.

NAFLD, which affects more than one-third of the world’s population, is characterized by excessive fat build-up in the liver due to causes other than alcohol use. There are two types of NAFLD: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Non-alcoholic fatty liver usually does not progress to liver damage or NASH. NASH includes both a fatty liver and liver inflammation. It may lead to complications such as cirrhosis, liver cancer, liver failure, or cardiovascular disease. NAFLD displays a strong genetic component, and inherited forms of have been suspected. However, the molecular mechanisms of hereditary NAFLD have not been described.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) identified a gene, that when mutated, causes NAFLD. This finding was made while the investigators were studying Chanarin-Dorfman syndrome, a severe but rare skin disorder, in several families from Iran. Sufferers of Chanarin-Dorfman syndrome develop dry, reddish, and scaly skin shortly after birth and later on in life acquire abnormally large and fatty livers.

The investigator performed whole-exome or targeted next-generation sequencing on patients from six families who demonstrated autosomal dominant NAFLD. From their results, the investigators described a heritable form of NAFLD and/or dyslipidemia due to monoallelic ABHD5 (abhydrolase domain containing 5) mutations, with complete clinical expression after the fourth decade of life. Mutations in the ABHD5 gene have been associated with Chanarin-Dorfman syndrome, a triglyceride storage disease with impaired long-chain fatty acid oxidation.

The results obtained during the present study came from seven unrelated multiplex families encompassing 39 affected individuals. The prevalence of ABHD5-associated NAFLD was estimated to be one in 1,137 individuals in a normal population.

“Studying a rare, heritable disease such as Chanarin-Dorfman syndrome, can be very helpful in identifying conditions which are much more prevalent, like in the case of non-alcoholic fatty liver disease,” said senior author Dr. Jouni Uitto, professor of dermatology and cutaneous biology at Thomas Jefferson University. “It turns out that if you have one mutated copy of the ABHD5 gene you get the liver disease only, but if you have mutations in both copies then you get the liver disease plus Chanarin-Dorfman syndrome.”

“The link between non-alcoholic fatty liver disease and scaly skin diseases such as Chanarin-Dorfman syndrome highlights the importance of regulated lipid metabolism in skin physiology,” said Dr. Uitto. “In fact, there are several heritable disorders manifesting with dry and scaly skin associated with mutations in genes like ABHD5 that are involved in lipid metabolism. Identification of such genes and specific mutations now form the basis for ongoing studies attempting to develop treatment for these often devastating skin disorders.”

The study was published in the August 2019 issue of the Journal of Hepatology.

Related Links:
Thomas Jefferson University

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.